Ítem
Solo Metadatos

Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up

Mostrar el registro sencillo de la publicación
dc.creatorArevalo, J. Fernandospa
dc.creatorFromow-Guerra, Jansspa
dc.creatorQuiroz-Mercado, Hugospa
dc.creatorSanchez, Juan G.spa
dc.creatorWu, Lihtehspa
dc.creatorMaia, Mauriciospa
dc.creatorBerrocal, Maria H.spa
dc.creatorSolis-Vivanco, Adrianaspa
dc.creatorFarah, Michel Espa
dc.date.accessioned2020-08-06T16:21:01Z
dc.date.available2020-08-06T16:21:01Z
dc.date.created2007-04spa
dc.description.abstractPurpose: To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME). Design: Interventional retrospective multicenter study at 6 centers from 6 countries of patients with DME. Participants: We reviewed the clinical records of 88 consecutive patients (110 eyes) with DME. Seventyeight eyes of 64 consecutive patients with a minimum follow-up of 6 months and mean age of 59.7 9.3 years were included in this analysiseng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1016/j.ophtha.2006.12.028
dc.identifier.issnISSN: 1549-4713
dc.identifier.issnEISSN: 0161-6420
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/26225
dc.language.isoengspa
dc.publisherElsevierspa
dc.relation.citationEndPage750
dc.relation.citationIssueNo. 4
dc.relation.citationStartPage743
dc.relation.citationTitleOphthalmology
dc.relation.citationVolumeVol. 114
dc.relation.ispartofOphthalmology, ISSN: 15494713, 01616420, Vol.114, No.4 (April, 2007); pp.743-750spa
dc.relation.urihttps://www.aaojournal.org/article/S0161-6420(07)00018-8/fulltextspa
dc.rights.accesRightsinfo:eu-repo/semantics/restrictedAccess
dc.rights.accesoRestringido (Acceso a grupos específicos)spa
dc.sourceOphthalmologyspa
dc.source.instnameinstname:Universidad del Rosario
dc.source.reponamereponame:Repositorio Institucional EdocUR
dc.subject.keywordAngiogenesis Inhibitorsspa
dc.subject.keywordAntibodiesspa
dc.subject.keywordMonoclonalspa
dc.subject.keywordAntibodiesspa
dc.subject.keywordMonoclonalspa
dc.subject.keywordHumanizedspa
dc.subject.keywordBevacizumabspa
dc.subject.keywordDiabetic Retinopathyspa
dc.subject.keywordFemalespa
dc.subject.keywordFluorescein Angiographyspa
dc.subject.keywordFollow-Up Studiesspa
dc.subject.keywordHumansspa
dc.subject.keywordInjectionsspa
dc.subject.keywordMacular Edemaspa
dc.subject.keywordMalespa
dc.subject.keywordMiddle Agedspa
dc.subject.keywordOphthalmoscopyspa
dc.subject.keywordRetrospective Studiesspa
dc.subject.keywordTomographyspa
dc.subject.keywordOptical Coherencespa
dc.subject.keywordTreatment Outcomespa
dc.subject.keywordVascular Endothelial Growth Factor Aspa
dc.subject.keywordVisual Acuityspa
dc.subject.keywordVitreous Bodyspa
dc.titlePrimary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-upspa
dc.title.TranslatedTitleBevacizumab intravítreo primario (Avastin) para los resultados del edema macular diabético del Grupo de Estudio Panamericano de Colaboración Retina a los 6 meses de seguimientospa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones
Artículos